Objective The objective of this retrospective study was to investigate the prognostic factors associated with survival among patients with extensive stage-small cell lung cancer（ES-SCLC）. Methods Clinical data from 66 patients with ES-SCLC diagnosed via histopathology or cytology between July 2005 and July 2009 at Anyang Tumor Hospital（China） were analyzed. Univariate and multivariate Kaplan-Meier, log-rank, and Cox proportional hazard regression analyses were conducted. Results The 12-, 24-, and 36-month survival rates among patients with ES-SCLC were 40.9%, 13.6%, and 6.1%, respectively. The median survival time（MST） was 10 months. Univariate analyses indicated that weight loss, efficacy of first-line chemotherapy, total number of chemotherapy cycles, treatment method, and serum sodium levels significantly influenced survival among patients with ES-SCLC. Multivariate analyses suggested that the efficacy of first-line chemotherapy, total number of chemotherapy cycles, and serum sodium levels were independent prognostic factors associated with survival. Conclusion The efficacy of first-line chemotherapy, total number of chemotherapy cycles, and serum sodium levels are important prognostic factors for patients with ES-SCLC.
展开▼
